Clinical Trial Update: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update indicates naxitamab is being added to induction therapy for newly diagnosed high-risk neuroblastoma, with patient recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Naxitamab (naxitamab)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING